Meet our Team

Oxion Biologics is run by a founding team of 6 scientists, physicians and entrepreneurs with previous combined experience of 70+ years in the medicine and biotech fields. The Oxionbio founder team holds credentials in wet lab, translational and clinical R&D, clinical operations and fundraising. as well as a successful record of bringing multiple biotech startups from pre-clinical ideas and discoveries into clinical development.

Click on the team members to learn more about them

Robin Fröbom

Robin Fröbom

Chief Executive Officer

Robin Fröbom, MD, PhD

Chief Executive Officer

Robin Fröbom is a physician-scientist with expertise in oncology and immunology. Robin co-led the development and optimization of OX118 and led the regulatory strategy. He is passionate about enabling next-generation therapeutics that achieve disease modification rather than reactive treatment of symptoms. Robin has published several papers on several therapeutics modalities within oncology and transplantation. Robin is an inventor on several patents. Robin received his clinical training in transplantation surgery and ENT/Head and Neck surgery at Karolinska University Hospital. Robin holds MD and PhD degrees from Karolinska Institutet. Robin is a director of Oxion Biologics.
Felix Sellberg

Felix Sellberg

Chief Scientific Officer

Felix Sellberg, MD, PhD

Chief Scientific Officer

Felix is a physician and researcher with expertise in immunology. He co-led OX118 preclinical development and led the evaluation and characterization of OX118. Felix maintains a lab working with co-stimulatory pathways in auto-immunity at Uppsala University, Sweden. He has led more than 5 projects from early pre-clinical development towards clinical translation. Felix received clinical training at Akademiska Sjukhuset, Uppsala, and holds MD and PhD degrees from Uppsala University. Felix is a director of Oxion Biologics.
Cheng Xu

Cheng Xu

Chief Operations Officer

Cheng Xu, MD, PhD

Chief Operations Officer

Cheng is a physician and researcher with expertise in gastroenterology and diabetology. He co-led OX118 preclinical development and led the target selection of Oxion Biologics' next-generation asset portfolio. Cheng is based in Zürich, Switzerland and Stockholm, Sweden. Cheng received clinical training at Karolinska University Hospital, and holds MD and PhD degrees from Karolinska Institutet. Cheng is a director of Oxion Biologics.